QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module X — Additional Monitoring of Medicinal Products

Test your understanding of the concepts covered by GVP Module X: Additional Monitoring of Medicinal Products.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A prescriber sees the inverted black triangle next to a medicine and asks whether this means the medicine should generally be avoided. What is the most appropriate response?

Yes, because the symbol indicates that the medicine is more dangerous than alternatives Yes, unless the patient has already used the medicine without an adverse reaction No; the symbol indicates a need for enhanced monitoring and reporting, while prescribing remains based on the authorised indication, evidence and patient-specific factors No; the symbol means that all clinically important risks have already been ruled out

Question 2 of 10 Two medicines both carry the black triangle. What can be inferred from that fact alone?

They have identical safety profiles and identical post-authorisation obligations They have the same underlying regulatory reason for additional monitoring They share the monitoring status, but their risks, evidence bases and regulatory circumstances may differ They have both been shown to have a negative benefit-risk balance

Question 3 of 10 Which communication would be misleading when explaining the black triangle to healthcare professionals?

Reporting suspected adverse reactions is particularly valuable for this medicine The medicine is subject to additional monitoring while safety experience develops or a concern is further characterised The symbol does not by itself establish that the medicine is unsafe The symbol proves that the medicine has a higher level of harm than medicines without the symbol

Question 4 of 10 What is the primary purpose of EU additional monitoring?

To identify medicines whose benefit-risk balance is considered negative To strengthen collection and visibility of post-authorisation safety information for selected medicines To exempt selected medicines from routine pharmacovigilance requirements To restrict prescribing until a medicine has accumulated sufficient real-world evidence

Question 5 of 10 An MAH's special additional-monitoring team receives reports but does not reliably transfer them into central signal detection. What is the principal weakness?

The team is collecting too much information for pharmacovigilance purposes The black triangle should be removed immediately The organisation has created fragmentation instead of integrating the information into the normal pharmacovigilance system Signal detection is not required for additionally monitored products

Question 6 of 10 Why can a medicine receive additional-monitoring status even when its benefit-risk balance was positive at authorisation?

Authorisation requires only limited quality testing for medicines under additional monitoring Pre-authorisation studies cannot fully observe all rare, delayed or population-dependent adverse reactions Additional monitoring is applied whenever the benefit-risk balance is uncertain at the time of authorisation A positive benefit-risk balance is not required for medicines with a new active substance

Question 7 of 10 Which product-information approach is consistent with the EU additional-monitoring framework?

Include the inverted black triangle together with the standard explanatory reporting statement Include the triangle without any accompanying explanation to avoid alarming patients Include a statement that the product is proven to be high risk Include the symbol only in internal pharmacovigilance documents

Question 8 of 10 Which type of information illustrates why the quality of an individual spontaneous report matters?

Only the total number of reports received during the quarter The product's sales revenue without any clinical details Clinical chronology, concomitant medicines, patient characteristics and outcome The presence of the black triangle on the package

Question 9 of 10 What is the most appropriate QPPV perspective on additional-monitoring arrangements?

The QPPV must personally perform every artwork and packaging update The QPPV should have assurance that the system incorporates the status and resulting safety information, with escalation of significant discrepancies or failures The QPPV has no role because additional monitoring is exclusively a regulatory-affairs responsibility The QPPV should treat additionally monitored products as outside the ordinary pharmacovigilance system

Question 10 of 10 Why should the current EU additional-monitoring list be used when verifying a product's status?

Because an MAH may apply or remove the status whenever it considers reporting useful Because additional monitoring is a controlled regulatory status that cannot reliably be inferred from product age or type alone Because the list contains only products with proven serious adverse reactions Because product information is not relevant to determining additional-monitoring status

Knowledge Assessment: GVP Module X — Additional Monitoring of Medicinal Products

Cookie Settings